Clinical Trials
15 trialsNCT05636111 2026-01-22
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05244239 2025-10-31
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Emory University
Phase 1 Recruiting
NCT05072106 2025-09-16
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT05063318 2025-09-02
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT04638491 2024-06-10
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Luye Pharma Group Ltd.
Phase 1 Completed
NCT04610658 2024-04-02
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT05101265 2023-11-27
Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
PharmaMar
Phase 1 Unknown
NCT01831089 2020-04-10
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT01970540 2020-03-09
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
PharmaMar
Phase 1 Completed
NCT01980667 2017-01-26
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
PharmaMar
Phase 1 Completed
NCT02210364 2016-12-14
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
PharmaMar
Phase 1 Completed
NCT01405391 2016-01-15
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
PharmaMar
Phase 1 Completed
NCT01314599 2015-11-05
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
PharmaMar
Phase 1 Completed
NCT00877474 2015-11-04
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT01970553 2015-04-01
Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
PharmaMar
Phase 1 Completed